Loading stock data…
TRVI
$15.27+0.51 (+3.46%)
Market ClosedLast close May 13
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $15.27. Wall Street consensus targets $23.45 (11 analysts), implying a +53.6% move over the next 12 months. The stock is currently near its 52-week high of $16.12, remaining 39.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$15.27
Potential Downside
0%
Whystock Fair Value$15.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$23.45+53.6%
Range$19.00 – $30.00
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.55%
Volume
Today's trading volume
1.90M
Recent News
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Trevi Therapeutics, Inc.'s Q1 2026 earnings call
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030
Trevi Therapeutics recently reported a first‑quarter 2026 net loss of US$13.19 million, broadly flat on a per‑share basis, while outlining plans to advance multiple chronic cough trials for its lead drug Haduvio. Alongside this, the company raised approximately US$162 million in a follow‑on offering, extending its cash runway into 2030 and supporting expanded clinical development and intellectual property efforts. We’ll now examine how the extended cash runway to 2030 reshapes Trevi’s...
Trevi Therapeutics Q1 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?
Trevi Therapeutics recently closed an underwritten public offering of 13,340,000 common shares, raising approximately US$173 million before fees, and separately proposed doubling its authorized common stock to 400,000,000 shares via an amendment to its Delaware certificate of incorporation. The combination of a sizeable capital raise and a request for significantly more authorized shares gives Trevi added financial flexibility for future financing, partnering or incentive programs without...